An interventional study of Verum Electroacupuncture and Sham Electroacupuncture in Dry Eye, sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Dry Eye Syndromes with a site in China — 28 open to participants now, 30 under way, 3 of them phase 3. Dry Eye Syndromes · China.
Among the 106 studies in Dry Eye Syndromes with a site in China, this one is the 20th largest by enrollment of the 83 interventional ones that give a count, is one of 16 that started in 2023, is one of 46 with no phase, and was the 48th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →28 of the 106 studies in Dry Eye Syndromes with a site in China are open now. Recruiting first, the newest first:
Ocumension Therapeutics (Suzhou) Co., Ltd · Sites in China
Ages 30–75
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18+
Shanghai Changzheng Hospital · Sites in China
Ages 18–70 · Healthy volunteers
Jin Yang · Sites in China
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 11 · Phase 3 11 · Phase 4 9
First in 2010; this study’s year is marked. 16 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 168 is above the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 80 across the 83 interventional studies, 100 across the 23 observational. Of the 50 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 106 have an industry lead sponsor. The 10 most frequent:
Shanghai Institute of Acupuncture, Moxibustion and Meridian is the lead sponsor of 29 studies on the registry; 5 are open to participants now.
Shanghai Institute of Acupuncture, Moxibustion and Meridian has 1 study filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
8 of the studies in Dry Eye Syndromes with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06360133Phase 3VivaVision Biotech, IncStudy of 5% VVN001 Ophthalmic Solution in Dry Eye Disease | 2027-04-30 |
| NCT07940452Eye & ENT Hospital of Fudan UniversityA Novel Eye Wash Solution for DED Treatment | 2026-11 |
| NCT07623382The First Affiliated Hospital of Xiamen UniversityHuman Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease | 2026-11-30 |
| NCT05605314Peking University Third HospitalClinical Cohort Study in Patients With Different Subtypes of Primary Sjogren Syndrome Related Dry Eye | 2027-01-01 |
| NCT07679685Beijing Tongren HospitalPerfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry Eye | 2027-02-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 106 studies in Dry Eye Syndromes with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine if electroacupuncture acts as an dry eye treatment rather than a placebo, and identify if benefits are linked to corneal subbasal nerve changes and neuroimmunomodulatory indicators.
Acupuncture is an important method in the treatment of diseases in Chinese medicine and plays an important role in the treatment of many diseases. Electroacupuncture (EA), as a combination of acupuncture and electric stimulation, is now widely used in research and clinical treatment. Our preliminary study found that compared with 0.1% sodium hyaluronate eye drops, EA exerted more beneficial and durable effects after four weeks of treatment. However, the placebo effect of EA cannot be ruled out yet. The aim of this study is to determine if EA acts as an dry eye treatment rather than a placebo, and identify if benefits are linked to corneal subbasal nerve changes.
This is a multicenter, randomized, subject-blinded, sham-controlled trial. A total of 168 participants with mild-to-moderate dry eye will be randomly assigned (1:1) to verum EA or non-penetrating non-acupoint sham EA (3 times weekly for 4 weeks), followed by a 24-week follow-up. The primary efficacy outcome is the change from baseline to week 4 in the Noninvasive Tear Breakup Time (NIBUT). Secondary efficacy outcomes include tear meniscus height (TMH), Schirmer I test (SⅠT), corneal topography, corneal and conjunctival sensation, scores of Ocular Surface Disease Index (OSDI), corneal fluorescein staining (CFS), Numerical rating scale (NRS), and Chinese Dry Eye Related Quality of Life Scale (CDERQOL) . Additionally, we will apply the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder (GAD-7) to understand the mental health conditions of patients. IVCM will be performed to observe the morphological changes of the corneal basal nerve. The changes of NGF, CGRP, NPY, 8-OHDG, 4-HNE, MDA and other neuroimmunomodulatory indicators in tears and conjunctival cells will be detected by immunofluorescence, ELISA, or other techniques.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Verum electroacupuncture treatment will be given 3 times a week, at least 1 day apart , for consecutive 4 weeks with a 24-week follow-up. Each session lasts for 30 min.
Device: Verum Electroacupuncture
Sham electroacupuncture on non-acupoints plus non-penetrating plus no electrical stimulation will be given 3 times a week, at least 1 day apart , for consecutive 4 weeks with a 24-week follow-up. Each session lasts for 30 min.
Device: Sham Electroacupuncture
Acupoints: Cuanzhu (BL2), Taiyang (EX-HN5), Sibai (ST1), Sizhukong (TE23), Baihui (GV20), Fengchi (GB20), Hegu (LI4), Zusanli (ST36), Guangming (GB23), Sanyinjiao (SP6), and Taichong (LR3). All acupoints will be taken bilaterally, except Baihui (GV20). The subject is placed in the supine position with eyes close. After routine sterilization, the sterile polyethylene cylindrical needle pad will be adhered to the acupoints. Then, the sterile acupuncture needles (0.25 mm×0.40 mm, Hwato brand, China.) will be inserted into the skin through the needle pad. Twirling and lifting-thrusting manipulations will be performed on the acupoints until Deqi is reported by the subject. Two pairs of electrodes will be connected at the needle handles on BL2 and EX-HN5 with a 2 Hz, continuous-wave electro-stimulation provided by the electroacupuncture apparatus (SDZ-Ⅲ type, Hwato brand, China). The pulse amplitude is about 1-2 mA.
Sham acupoints: SA1(1 cm above BL2), SA2 (1 cm above SJ23),SA3 (1 cm above EX-HN5), SA4 (1 cm lateral to ST2), SA5 (the midpoint of the line between GV20 and right EX-HN1), SA6 (the midpoint of the line between GB20 and SJ16), SA7 (1 cm lateral to LI4), SA8 (the midpoint of the line between ST36 and GB34), SA9 (the midpoint of the line between GB37 and BL58), SA10 (1 cm backward to SP6), SA11 (the midpoint of the line between LR3 and SP4). After routine sterilization, placebo needles will be used (Streitberger, Asia-med GmbH). The tingling sensation produced when the Streitberger needle is fixed on the skin causes the subject to believe that the needle is piercing the skin, simulating a skin puncture. The electric stimulator is applied to bilateral SA1 and SA3 with no current output. The exterior appearance, indicator light, prompt tone of the sham device, and stimulation parameters are all indistinguishable from the normal one.
Change from Baseline in Noninvasive Tear Breakup Time (NIBUT)
The interval between a complete blink and the first breakup of tear film (indicated by a break or deformed Placido disc image on the screen) will be recorded. The measurements are carried out 3 times and the average value is considered as NIBUT.
Time frame: Baseline, Week 4, Week 8, Week 16, Week 28
Change From Baseline in Tear Meniscus Height (TMH)
The digital slit lamp (SL990N, CSO, Italy) is applied to take images of the tear meniscus at the lower lid margin in a dark room. The tear meniscus height directly below the central pupil is measured with the system's built-in caliper tool.
Time frame: Baseline, Week 4, Week 8, Week 16, Week 28
Change From Baseline in Ocular Surface Disease Index (OSDI)
The OSDI scale is used to assess subjective symptoms related to dry eye, including ocular symptoms, visual function and environmental triggers, with a total score ranging from 0 to 100. The higher the score, the more severe the subjective symptoms.
Time frame: Baseline, Week 4, Week 8, Week 16, Week 28
Change From Baseline in Corneal Fluorescein Staining (CFS)
Sodium fluorescein ophthalmic strips (Tianjin Jingming New Technology Development Co., Ltd., China) are used to evaluate corneal epithelial damage. According to the Oxford grading scheme, the CFS score ranges from 0 (no damage) to 5 (severe damage).
Time frame: Baseline, Week 4, Week 8, Week 16, Week 28
Change From Baseline in Corneal Topography
The corneal topography system is used to take photographs. The subjects are asked to blink naturally 3 to 4 times, and after the last full blink, they look at the central light source of the Placido disk for 10 s. The researchers take photographs of the anterior corneal surface immediately after the blink and at 10 s of continuous gaze. The SRI and SAI are systematically analyzed and obtained at 10 s.
Time frame: Baseline, Week 4, Week 8, Week 16, Week 28
Change From Baseline in Corneal and Conjunctival sensation
The Cochet-Bonnet perception meter (Luneau Chartres, France) will be used to evaluate the corneal perception (including central, superior, inferior, nasal, and temporal corneas, all 2 mm from the corneal rim) and conjunctival perception (including temporal and nasal bulbar conjunctivae, both 3 mm from the corneal rim; superior and inferior conjunctiva, at the center of the eyelid). The measured fiber length will be converted to g/mm2 according to the criteria provided by the supplier, with a higher threshold indicating a more insensitive perception.
Time frame: Baseline, Week 4, Week 8, Week 16, Week 28
Change From Baseline in Schirmer I test (SⅠT)
SⅠT will be performed using a tear detection filter strip (Tianjin Jingming New Technology Development Co., Ltd., China). Patients are requested to avoid eye movement. The strips will be removed after 5 min, and recorded the wetting length.
Time frame: Baseline, Week 4, Week 8, Week 16, Week 28
Change From Baseline in Numerical Rating Scale (NRS)
Subjects are asked to rate their current Iocular pain intensity in the right and left eye (0-10 numerical rating scale, NRS) followed by placement of 0.4% hydroxybuprocaine hydrochloride (Santen Pharmaceutical Co., LTD., Japan), and rerating of pain 30 seconds later.
Time frame: Baseline, Week 4, Week 8, Week 16, Week 28
Change From Baseline in Chinese Dry Eye Related Quality of Life Scale (CDERQOL)
CDERQOL includes 5 domians containing 45 items rated on a 5-point Likert scale ranging from 1 (completely disagree) to 5 (completely agree).
Time frame: Baseline, Week 4, Week 8, Week 16, Week 28
Adverse events
Any adverse events will be recorded. EA-related adverse events include local bleeding, subcutaneous hematoma, pain, itch, infection, and generalized symptoms such as dizziness and palpitation during treatment.
Time frame: Week 4
Change From Baseline in Generalized Anxiety Disorder (GAD-7)
The scale consists of 7 items with 4 frequency options for each question, ranging from "not at all (0)" to "almost every day (3)", with the following criteria: no anxiety (0-4); mild anxiety (5-9); moderate anxiety (10-14); and severe anxiety (15-21). 14 points); and severe anxiety (15-21 points).
Time frame: Baseline, Week 4, Week 8, Week 16, Week 28
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9)
The scale consists of 9 items with 4 frequency options for each question, ranging from "not at all (0)" to "almost every day (3)", with the following criteria: no depression (0-4); mild depression (5-9); moderate depression (10-14); moderate to severe depression (15-19); and severe depression (20-27). 14 points); moderate to severe depression (15-19 points); and severe depression (20-27 points)
Time frame: Baseline, Week 4, Week 8, Week 16, Week 28
Change in morphological changes of the corneal basal nerve
In vivo confocal microscopy (IVCM) is performed to initially observe the morphological changes of the corneal basal nerve. IVCM images are taken with a Heidel-berg Retina Tomograph III (HRT III; Heidelberg Engi¬neering, Germany). The ACCMetrics analysis software (M.A. Dabbah, lmaging Science Biomedical Engineering, Manchester, UK) is used to calculate nerve morphological parameters for the selected images.
Time frame: Baseline, Week 4
Change in neuroimmunomodulatory indicators in tears and conjunctival cells
Schirmer test strip is s used to collect tears from patients before and after treatment. Conjunctival impression cytology is used to obtain conjunctival cells. Immunofluorescence, ELISA and other techniques are used to detect the changes in NGF, CGRP, NPY, 8-OHDG, 4-HNE, MDA and other neuroimmunomodulatory indicators in tears and conjunctival cells of subjects.
Time frame: Baseline, Week 4
Ran from Dec 2023 to primary completion in Oct 2025, 22 months.
Of 200 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's 22 months is above that.
Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Institute of Acupuncture, Moxibustion and Meridian